RT Conference Proceedings
T1 MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
A1 Piccart, M.
A1 Borrego, M. Ruiz
A1 Arkenau, H-T.
A1 Escriva-De-Romani, S. I.
A1 Howell, S. J.
A1 Hennequin, A.
A1 Jimenez-Rodriguez, B.
A1 Del Conte, G.
A1 Simonelli, M.
A1 Palleschi, M.
A1 Duhoux, F.
A1 De Speville Uribe, B. Doger
A1 Curigliano, G.
A1 Waters, S.
A1 Aftimos, P. G.
A1 Wildiers, H.
A1 Tosi, D.
A1 Amair-Pinedo, F.
A1 Pellacani, A. U. E.
A1 Laurent, D. O.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27098
UL https://hdl.handle.net/10668/27098
LA en
DS RISalud
RD Apr 5, 2025